U.S. Stock Market Anomalies | Q1 earnings fall short of expectations, Vertex Pharmaceuticals (VRTX.US) plunges more than 12%

According to the Wise Financial APP, on Tuesday, Fulite Pharmaceuticals (VRTX.US) fell by more than 12%, potentially hitting the largest decline since October 15, 2020, to $438.74. On the news front, the company reported a first-quarter non-GAAP diluted earnings per share of $4.06 on Monday evening, lower than the $4.76 a year ago, while analysts surveyed by FactSet had expected $4.25. Operating income was $27.7 billion, slightly higher than the $26.9 billion in the same period last year, with analysts surveyed by FactSet expecting $28.6 billion. The company revised its full-year revenue guidance for 2025 to $11.85 billion to $12 billion, up from $11.75 billion to $12 billion, with analysts expecting $11.99 billion.